fluoxetine / Generic mfg. - LARVOL DELTA

Exploring the antidepressant-like effect of stigmasterol using network pharmacology with molecular docking and in vivo experimental validation. (PubMed, Sci Rep) - "STG demonstrated significant antidepressant-like effects similar to fluoxetine-treated mice in both FST and TST. This antidepressant action was significantly influenced by serotonin neurotransmission. Overall, we confirmed the antidepressant-like activity of STG and its possible multitarget potential in depression management."

Journal • Preclinical • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry • AKT1 • IL1B • SLC6A4 • TP53

Clinical outcomes in patients with multiple myeloma and antidepressant use: A retrospective cohort study (ASH 2025) - "Adult patients with multiple myeloma since 2010 and prescribed antidepressants (sertraline, escitalopram, citalopram, paroxetine, fluoxetine, fluvoxamine, venlafaxine, duloxetine, trazodone, mirtazapine, or bupropion) were identified using ICD-10 diagnostic and RxNorm codes. While some associations were modest in magnitude, the consistent pattern of increased risk suggests that pre-existing depression and its treatment may identify a more vulnerable subgroup of multiple myeloma patients. Further prospective studies are needed to clarify underlying mechanisms and to evaluate the potential impact of early psychiatric intervention."

Clinical data • Retrospective data • Chronic Kidney Disease • CNS Disorders • Depression • Hematological Malignancies • Infectious Disease • Major Depressive Disorder • Multiple Myeloma • Musculoskeletal Diseases • Nephrology • Renal Disease

Peripubertal PTSD-like stress in rats induces transient behavioral but lasting metabolic and inflammatory alterations: Limited fluoxetine efficacy. (PubMed, Pharmacol Biochem Behav) - "Fluoxetine partially normalized behavior but failed to prevent long-term biochemical and hematological alterations. These highlight the systemic and time-dependent consequences of peripubertal PTSD and its pharmacological treatment, underscoring the need for longitudinal monitoring of physiological outcomes alongside recovery of behavioral phenotype."

Journal • Preclinical • CNS Disorders • Hematological Disorders • Inflammation • Mood Disorders • Post-traumatic Stress Disorder • IL6

Uterotropic response to the antidepressant fluoxetine (Prozac) is dependent on a functional serotonin transporter and circulating serotonin. (PubMed, Sci Rep) - "In mice with genetic ablation of the serotonin transporter (Slc6a4-/-, target site for SSRI) and depleted peripheral (nonneuronal) synthesis of serotonin (Tph1-/-), fluoxetine did not elicited uterotropic response. Therefore, the uterotropic response to fluoxetine is dependent on inhibition of serotonin transporter function and mediated by circulating serotonin."

Journal • ER • IGFBP3 • SLC6A4

The Comparative Efficacy of Antidepressant and Psychological Therapies on Cognition in Depression: A Systematic Review and Network Meta-Analysis. (PubMed, Neuropsychol Rev) - "Common antidepressants, including escitalopram, citalopram, paroxetine and fluoxetine were not significantly different from placebo in improving cognition. The findings suggest that, among antidepressants, vortioxetine is the sole treatment improving cognition in depression. The effects were however small, highlighting the need for the development of MDD interventions targeting cognition."

Journal • Retrospective data • Review • CNS Disorders • Cognitive Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

Dual Modulation of 5-HT2A Receptors and SERT by α-Ethyltryptamine and Its Optical Isomers. (PubMed, ACS Chem Neurosci) - "Notably, pretreatment with fluoxetine abolished AET-induced HTR without affecting responses to the classical psychedelic DOI, implicating SERT-mediated serotonin release in AET's mechanism of action. These findings indicate that AET's behavioral effects rely on a dual mechanism involving both direct 5-HT2AR activation and indirect serotonergic potentiation via SERT. This dual pharmacology distinguishes AET from classical psychedelics and places it within a unique niche alongside MDMA-like serotonergic agents, highlighting the therapeutic and neuropsychiatric potential of AET isomers for modulating mood and cognition."

Journal • Psychiatry

Antidepressant-Like Effect of an Immediate-Release Formulation of Mallotus oppositifolius in Mice. (PubMed, Scientifica (Cairo)) - "Except for the vehicle nonstressed (VEH-NS) group, mice were subjected to the UCMS for 7 weeks while receiving normal saline (VEH-S, 10 mL/kg; p.o.), MOE-IR (10, 30, and 100 mg/kg; p.o.), or fluoxetine (FLX 20 mg/kg; p.o.) daily for 5 weeks...MOE-IR decreased the plasma corticosterone concentration and increased the dentate gyrus (DG) dendritic spine density. Collectively, MOE-IR demonstrated antidepressant-like that may be associated with antioxidant effects, decreased plasma corticosterone levels, and increased DG dendritic spine density."

Journal • Preclinical

Removal of contaminants from wastewater using the bivalve Corbicula fluminea - Comparative assessment of biofiltration and biosorption. (PubMed, J Environ Manage) - "Clams were more effective than shells in removing fluoxetine, paracetamol, carbamazepine, metformin and diclofenac whereas the opposite was observed for caffeine and naproxen. Indeed, the remarkable toxicity reduction to the microalgae exposed to the biofiltered fluoxetine sample matches the pronounced removal %, confirming the beneficial effect of C. fluminea on the quality of water contaminated with this compound. Although biofiltration outperformed biosorption in general, the requirements for clams' maintenance and the risk of spreading this invasive species might constitute a drawback for the use of this species for bioremediation of contaminated wastewaters, highlighting the importance of analyzing the pros and cons of these approaches for each specific application."

Journal

Adjustment for dispensed doses does not explain higher antidepressant concentrations in post-mortem toxicology. (PubMed, Br J Clin Pharmacol) - "Dose adjustment generally did not improve the separation of poisoning vs non-poisoning suicides, indicating that post-mortem concentrations may not have clear dose-concentration relationships."

Journal

Growth factor receptor-bound protein 2-mediated corneal epithelial injury drives depression-associated dry eye disease. (PubMed, Biochem Pharmacol) - "These findings highlight GRB2 as a potential therapeutic target and underscore fluoxetine's dual efficacy in mitigating depressive symptoms and ocular surface damage. This study provides novel insights into the molecular interplay between depression and DED, advocating for integrated therapeutic strategies addressing both psychiatric and ophthalmic dimensions."

Journal • CNS Disorders • Corneal Abrasion • Depression • Dry Eye Disease • Inflammation • Ocular Inflammation • Ophthalmology • Psychiatry • GRB2

Ribociclib drug-drug interaction and concomitant medication management in early and advanced breast cancer patients (SABCS 2025) - "Background: Ribociclib is approved for the treatment of HR+/HER2- advanced or metastatic breast cancer (ABC) in combination with an aromatase inhibitor or fulvestrant, and more recently, for the adjuvant treatment of HR+/HER2- stage II and III early breast cancer (EBC) at high risk of recurrence, with the starting dose of 600 mg in ABC and 400mg in EBC...The effect of ribociclib on rosuvastatin, pravastatin, pitavastatin, and fluvastatin is considered minor with no clinical relevance, since these statins are not sensitive CYP3A4 substrates...No clinically relevant DDI is expected for commonly used antidepressants/antipsychotics, such as citalopram, escitalopram, fluoxetine, mirtazapine, sertraline, trazodone, venlafaxine, aripiprazole, olanzapine and cariprazine, when co-administered with ribociclib 400 mg or 600 mg... No clinically relevant DDI with ribocicilib is anticipated for commonly used statins or antidepressants/antipsychotics, except simvastatin, lovastatin,..."

Clinical • Metastases • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • HER-2

Enhancing Recruitment Using Teleconference and Commitment Contract (ERUTECC): a stepped wedge cluster randomised trial within the EFFECTS trial. (PubMed, Ups J Med Sci) - "Recruitment to Efficacy oF Fluoxetine - a randomisEd Controlled Trial in Stroke (EFFECTS), fluoxetine for stroke recovery was slower than anticipated...A teleconference with the study personnel and the head of department increased the recruitment by 23% within 30 days and by 10%, 60 days post intervention in this embedded RCT. This implies that this structured intervention aimed at increased recruitment was short-lived and would need frequent repetitions in order to be effective."

Clinical • Journal • Cardiovascular

New antidepressant diterpenoid alkaloids from Aconitum carmichaelii Debeaux: Potential inhibitors of NLRP3 activation. (PubMed, Bioorg Chem) - "Notably, compound 1 revealed remarkable antidepressant effects in the tail suspension test (TST) of mice at a dose of 0.1 mg/kg, with efficacy comparable to the positive control fluoxetine (10 mg/kg)...Finally, cellular thermal shift assay (CETSA) and molecular docking studies confirmed that 1 might acted as an inhibitor of NLRP3 activation. These findings provide a rationale for designing NLRP3 activation inhibitors as novel antidepressant agents."

Journal • CNS Disorders • Depression • Psychiatry • NLRP3

Large-scale integration of omics and electronic health records to identify potential risk protein biomarkers and therapeutic drugs for cancer prevention. (PubMed, Am J Hum Genet) - "Analyzing >3.5 million electronic health records, we conducted analyses of emulated trials for 11 drugs across 290 comparisons and identified three drugs significantly associated with reduced colorectal cancer risk: caffeine vs. paroxetine (hazard ratio [HR], 0.51; 95% confidence interval [CI], 0.41-0.64), haloperidol vs. prochlorperazine (HR, 0.47; 95% CI, 0.33-0.68), and trazodone hydrochloride vs. paroxetine (HR, 0.49; 95% CI, 0.38-0.63). Conversely, caffeine was associated with increased cancer risk in comparison with finasteride (colorectal cancer) and fluoxetine (breast cancer). Meta-analysis identified six drugs significantly associated with cancer risk, including acetazolamide, which was associated with reduced colorectal cancer risk (HR, 0.79; 95% CI, 0.72-0.87). This study identifies previously unreported protein biomarkers and candidate drug targets across six major cancer types and highlights several approved drugs with potential chemopreventive effects."

Biomarker • Journal • Breast Cancer • Colorectal Cancer • Genito-urinary Cancer • Oncology • Pancreatic Cancer • Prostate Cancer • Solid Tumor

A comparative assessment of the antidepressant efficacy of ketamine, psilocybin, and fluoxetine in a chronic stress model. (PubMed, Sci Rep) - "These findings suggest that ketamine and psilocybin elicit rapid and durable, antidepressant-like responses in this preclinical model, in contrast to traditional SSRIs, like fluoxetine, which requires extended treatment duration, mirroring clinical efficacy patterns. The results support the utility of the CSD model in evaluating antidepressant efficacy and highlight the therapeutic potential of fast-acting agents such as ketamine and psilocybin as alternatives to conventional treatments for major depressive disorder."

Journal • CNS Disorders • Depression • Major Depressive Disorder • Mental Retardation • Mood Disorders • Psychiatry

Phenobarbital for Refractory Behavioral Disturbances in Anti-NMDAR and HSV Encephalitis: A Case Report. (PubMed, J Pain Palliat Care Pharmacother) - "Disease-modifying therapies, including IV acyclovir, IV immunoglobulin, prednisone, and rituximab, were ineffective. Multiple psychotropic medications, including fluoxetine, quetiapine, olanzapine, and trazodone, failed to relieve behavioral symptoms...No adverse effects were reported. This case suggests that low-dose oral phenobarbital may be a viable option for managing refractory behavioral disturbances in patients and improving quality of life with anti-NMDAR and HSV encephalitis."

Journal • CNS Disorders • Herpes Simplex • Immunology • Insomnia • Mental Retardation • Palliative care • Psychiatry • Sleep Disorder

Effects of Compound Kushen Injection on the Pharmacokinetics of Fluoxetine in Rats. (PubMed, Biomed Chromatogr) - "Compared with those in the control group, the AUC(0-∞), Cmax, and T1/2z of FLX in the experimental group increased by 457.06%, 248.25%, and 90.62%, respectively, while CL/F, Vz/F, and Tmax decreased by 74.14%, 60.49%, and 41.11%, respectively. These findings demonstrate that CKI coadministration markedly alters FLX pharmacokinetics, potentially impacting treatment efficacy and safety."

Journal • PK/PD data • Preclinical • CNS Disorders • Depression • Oncology • Psychiatry

Efficacy and safety of antimigraine therapy with or without fluoxetine for migraine: A systematic review and meta-analysis (EHF-EHC 2025) - "However, evidence for cure rates remains inconclusive. Given the limited number and variable quality of included trials, further large-scale, rigorously designed randomized controlled trials are needed to confirm these findings and to better define the role of fluoxetine in antimigraine regimens."

Retrospective data • Review • CNS Disorders • Migraine • Pain

Physostigmine modulates hippocampal GABAergic neurotransmission via α7 nicotinic acetylcholine receptors. (PubMed, Neuropharmacology) - "In conclusion, physostigmine increases GABAergic synaptic transmission in hippocampal CA1 stratum radiatum interneurons acting as a type I positive allosteric modulator on tonic endogenous activated α7 nAChRs. These effects of physostigmine might be counteracted by fluoxetine, through inhibition of α7 nAChRs."

Journal • CNS Disorders • Depression • Psychiatry

Cannabidiol induces antiallodinic and antihiperalgesic effects via D2-NFKB dopamine receptor in hemiparkinsonian male rats (Neuroscience 2025) - "Most patients with Parkinson's disease have neuropathic pain and do not receive adequate treatment or do not respond to treatment, even though there are various first-line treatments, such as tricyclic antidepressants, gabapentin, pregabalin, duloxetine and fluoxetine. There are alternative treatments such as lidocaine or capsaicin patches, opioids, and cannabis...On the other hand, we find a decrease in NFKB immunoreactivity and cytokines production. These results show that CBD has analgesic activity and exerts it effect by D2DR via NFKB in 6-OHDA-lesion male rats."

Preclinical • CNS Disorders • Depression • Mood Disorders • Movement Disorders • Neuralgia • Parkinson's Disease • Psychiatry • Schizophrenia • DRD2

Effect of electroacupuncture at "Hegu" (LI4) and "Taichong" (LR3) on DNA methylation of the SLC6A4 gene promoter in the hippocampus of depressed rats (PubMed, Zhongguo Zhen Jiu) - "Thirty male Sprague-Dawley rats were randomly divided into a blank group, a model group, a medication group, a 5-Azacytidine (5-AZA) group, and an EA group, 6 rats in each group...The medication group was treated with intragastric administration of fluoxetine hydrochloride capsules; the 5-AZA group was treated with intraperitoneal injection of 5-AZA; the EA group was treated with EA at bilateral "Hegu" (LI4) and "Taichong" (LR3), with disperse-dense wave, frequency of 2 Hz/100 Hz, and intensity of 1-1.2 mA, 20 min each session...EA could improve depressive behaviors in depressed rat models. The underlying mechanism may involve inhibition of SLC6A4 hypermethylation in the hippocampus on the serotonergic system, upregulation of SLC6A4 and 5-HT1AR protein and mRNA expression, and elevation of monoamine neurotransmitters such as 5-HT."

Journal • Preclinical • CNS Disorders • Depression • Psychiatry • SLC6A4

Opioid overdose associated with concomitant use of hydrocodone and selective serotonin reuptake inhibitors. (PubMed, BMC Med) - "In this cohort study, based on data from US healthcare claims databases, initiating citalopram, escitalopram, fluoxetine, or paroxetine while on hydrocodone was associated with an increased risk of opioid overdose compared with sertraline. No substantial risk differences were observed across SSRIs other than sertraline."

Journal • Retrospective data • Addiction (Opioid and Alcohol) • CNS Disorders • CYP3A4

Exploring early add-on celecoxib treatment in OCD: Results from a preliminary randomized, double-blind, placebo-controlled trial. (PubMed, J Psychopharmacol) - "Celecoxib holds promise as a potentially safe early add-on treatment in OCD for rapid improvement in psychopathology, with further research warranted in this area."

Clinical • Journal • Inflammation • Mood Disorders • Obsessive-Compulsive Disorder • Psychiatry • BDNF • IL6

Effects of CYP2C9 genetic polymorphism and drug-drug interactions on trimethoprim metabolism. (PubMed, Biochem Pharmacol) - "Mechanistically, fluoxetine exhibited a competitive inhibition in RLM and a combination of competitive and non-competitive inhibition in HLM on trimethoprim metabolism. Our findings highlighted the significant impacts of CYP2C9 gene polymorphisms and fluoxetine on trimethoprim metabolism, providing insights for the precise administration of trimethoprim."

Journal • Psychiatry • CYP2C9

Effects of Saikosaponin A on Post-Traumatic Stress Disorder-Like Behaviors, Hippocampal Monoaminergic Neurotransmission, and the NF-κB Inflammatory Pathway in a Rat model. (PubMed, Behav Brain Res) - "Rats were randomly assigned to control, model, SSa treatment, and fluoxetine-positive control groups...Mechanistically, SSa restored depleted hippocampal 5-HT levels, reduced pro-inflammatory cytokines expression (TNF-α, IL-6, IL-1β), and suppressed NF-κB p65 activation. These findings demonstrate that SSa exerts therapeutic effect against PTSD-like behavior through dual mechanisms: restoration of hippocampal serotonergic neurotransmission and suppression of NF- κB- mediated neuroinflammation, positioning SSa as a promising candidate for PTSD treatment."

Journal • Preclinical • CNS Disorders • Inflammation • Mood Disorders • Oncology • Post-traumatic Stress Disorder • Psychiatry • IL1B • IL6 • TNFA